Ready-to-drink teas can provide, if properly packaged, the taste and wellness character of traditional teas. Nevertheless, in tea processing, there may be several contaminations, among which polycyclic aromatic hydrocarbons (PAHs), anthropogenic contaminants that can present carcinogenic and mutagenic properties. In this work, a novel low-density deep eutectic solvent-based dispersive liquid-liquid microextraction (LDDES-DLLME) procedure followed by gas chromatography tandem mass spectrometry (GC-MS/MS) was optimized for analysis of 15 polycyclic aromatic hydrocarbons (PAHs) in ready-to-drink herbal-based beverages. The new deep eutectic solvent (DES) was synthesized with natural compounds (camphor and hexanoic acid). Several parameters of the extraction procedure such as type and volume of extraction solvent, type, volume of dispersive solvent, and time of extraction were evaluated to achieve the highest yield and to attain the lowest detection limits. The validated method showed very low limits of detection (0.01 μg L-1) and quantification (0.2 μg L-1), good inter- and intra-day precisions (RSD less then 16.87%), and recoveries higher than 69%. The method was applied to 16 type of samples and it was found total PAHs levels ranging from 0.20 to 1.82 μg L-1. The developed LDDES-DLLME showed a reliable and innovative alternative for the extraction of PAHs from beverages, cost-effective and environmentally friendly, and providing a satisfactory throughput.Fast and highly efficient digestion of proteins is essential for high-throughput proteomic analysis. Herein, a facile approach was developed for self-assembly preparation of trypsin-immobilized capillary monolithic column and its application as an immobilized enzyme microreactor (IMER) for fast and highly efficient proteolysis was described. The performance of the trypsin-immobilized monolithic enzyme microreactor was evaluated by in-situ digestion of model proteins. The results showed that the trypsin-immobilized monolithic enzyme microreactor had much higher tryptic digestion efficiency than the free trypsin in solution, where the coverage of peptide sequences by mass spectrometry (MS)-based analysis could bear comparison with the free one, while the digestion time was dramatically shortened from 12 h to 16 s. Furthermore, the trypsin-immobilized monolithic enzyme microreactor also exhibited good practicability to complex human serum sample, in which the total of 45 peptides from human serum albumin (HSA) matched with sequence coverage of 75% were precisely identified.  https://www.selleckchem.com/products/elexacaftor.html  The successful application demonstrated the promising potential of the trypsin-immobilized capillary monolithic column as the IMER in high-throughput proteomic analysis.Recently, we developed a new approach for the selective enrichment of low-abundance compounds in biological samples by capillary electrophoresis. As a model test, the low-abundance compound lysozyme was successfully fractionated from a mixture containing high-abundance compound BSA (14500) using a custom-made apparatus. The feasibility of this approach for real complex biological samples was verified by rat serum, wherein three low-abundance proteins with high charge/mass ratios were detected.Novel montmorillonite composites including ionic liquid were prepared and utilized as coating materials for solid phase microextraction fibers. Ionic liquids containing amino terminated imidazolium cations with methyl and benzyl groups and hydrophobic anions (bis(trifluoromethylsulfonyl)imide) and hydrophilic anions (bromide and tetrafluoroborate) were intercalated to KSF-montmorillonite using stainless steel wire as support by using the layer-by-layer technique. After optimization of experimental conditions, solid phase microextraction (SPME) coupled to gas chromatography/mass spectrometry (SPME-GC/MS) after derivatization by silylation and high performance liquid chromatography/diode array detector (SPME-HPLC/DAD) were developed for the determination of 16 phenolic compounds. The developed SPME-GC/MS method had wider linearity and lower limit of detection than the developed SPME-HPLC/DAD method with similar repeatability (for 5 runs, less than 4.2 %) for a single fiber. The percentage of the variance between two different fibers was less than 6.0 % in both methods. The developed SPME methods were applied successfully to fresh fruit juices and the relative recoveries and the repeatabilities from spiked fruit juice samples were satisfactorily achieved. The results obtained with both chromatographic methods were in good agreement with each other.
  Real-world data on cabozantinib in metastatic renal cell carcinoma (mRCC) is limited. This study (CABOREAL) reports treatment patterns and outcomes for patients treated with cabozantinib through the French Early Access Program.
 
  This multicentre (n=26), observational, retrospective study enrolled patients with mRCC who had received ≥1 dose of cabozantinib. Overall survival (OS) was estimated using the Kaplan-Meier method; subgroups were compared using the log-rank test. A multiple Cox regression model assessed predictive factors of OS after cabozantinib initiation.
 
  Four hundred and ten recruited patients started treatment between September 2016 and February 2018 the Eastern Cooperative Oncology Group Performance Status ≥2, 39.3%; poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk, 31.7%; 0-1, 2 and ≥3 previous treatment lines, 25.3%, 33.4% and 41.2%, respectively; bone metastases, 55.9%; brain metastases, 16.8%. Median (min-max) follow-up was 14.4 (0-30) months. Overall, 57.0% of patients had a dose reduction, 15.6% an alternative dose schedule. The median average daily dose was 40.0mg. Median (quartile [Q]1-Q3) treatment duration was 7.6 (0.1-29.1) months, median OS was 14.4 months, and the 12-month OS rate was 56.5% (95% confidence interval 51.5-61.2). Most patients (54.4%) received subsequent treatment. Predictive factors associated with longer OS were body mass index ≥25kg/m
  (p=0.0021), prior nephrectomy (p=0.0109), favourable or intermediate IMDC risk (p<0.0001) and cabozantinib initiation at 60mg/day (p=0.0486).
 
  In the largest real-world study to date, cabozantinib was effective in unselected, heavily pretreated patients with mRCC. Initiation at 60mg/day was associated with improved outcomes. CLINICALTRIALS.
 
  NCT03744585.
 NCT03744585.